I've spoken to a consultant from clarity in 2020 and the goal is to definitely get bought out.
They can go the Telix way tho.
Telix is netting 100m AUD per quarter on their PSMA diagnostic. Pylarify by Lantheus is netting 520M USD per year.
Their diagnostic could be in the approval stage by 2025-2026.
Then you'll have Pluvicto to compare Cu67 SAR-bisPSMA, they are experiencing manufacturing issues and are still netting 200-250M USD a quarter. But we are 2028-2029 approvals away from that.
I've spoken to a consultant from clarity in 2020 and the goal is...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.01 |
Change
-0.340(4.63%) |
Mkt cap ! $2.244B | |||
| Open | High | Low | Value | Volume |
| $7.39 | $7.44 | $6.87 | $7.431M | 1.054M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3289 | $7.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.04 | 4050 | 1 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |